Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

NCT03812770 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib
DRUG: HAIC of FOLFOX
DRUG: HAIC of OXA

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]